Stock Market News 17 November 2025

AMD stock price today, 17 November 2025 Advanced Micro Devices (NASDAQ: AMD) is trading lower today as Wall Street digests another wave of AI‑related headlines and a fresh rumor about GPU price hikes. Even with today’s pullback, AMD remains up sharply year‑to‑date and is still priced for very high growth expectations in AI and data center computing. The key AMD headlines on November 17, 2025 Here are the main news items specifically about AMD stock today, 17.11.2025, that traders are reacting to: Taken together, today’s news flow is overwhelmingly about AI: massive long‑term opportunity, big partnerships, and ambitious targets —

Published: November 17, 2025 Key takeaways What moved Oracle stock today Jefferies sticks with $400 target, sees selloff as overdone.In a note published this morning, Jefferies’ Brent Thill reaffirmed a $400 target on Oracle, framing the recent drawdown as an opportunity. The call cites a still‑large non‑OpenAI backlog and argues Oracle’s capex approach limits upfront cash strain versus owning all the infrastructure outright. MarketWatch Hedging picks up in credit markets—Oracle included.An exclusive from Reuters says Saba Capital has been selling CDS protection on Oracle, Microsoft, Meta, Amazon, and Alphabet to banks seeking to hedge exposure to the sector’s accelerating, debt‑financed

Amazon (NASDAQ: AMZN) traded modestly lower at midday on Monday as the company launched its first U.S. dollar bond sale in three years—an issuance that swelled to about $15 billion amid heavy demand. As of 12:30 p.m. ET (17:30 UTC), AMZN changed hands at $233.53, down roughly 0.5% on the session. Bloomberg Key numbers (intraday) What’s moving AMZN today A jumbo bond sale to feed AI and growth spending. Amazon filed a six‑part U.S. investment‑grade offering that initially circulated around $12 billion, with the longest 40‑year tranche first guided at about +115 bps over comparable Treasuries. By afternoon, reporting indicated

LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss market LifeMD Announces $199 Cash-Pay Pricing for Wegovy and Ozempic This morning, LifeMD, Inc. (NASDAQ: LFMD) unveiled what it calls the lowest cash‑pay pricing available nationwide for the GLP‑1 weight‑loss drugs Wegovy and Ozempic, in continued collaboration with Novo Nordisk. MarketScreener+3GlobeNewswire+3Quiver Quantitative+3 Under the new offer: The move builds on LifeMD’s shift away from compounded GLP‑1s toward direct partnerships with